EMERGENT BIOSOLUTIONS INC. Goodwill, Impaired, Accumulated Impairment Loss
EMERGENT BIOSOLUTIONS INC. (EBS) had Goodwill, Impaired, Accumulated Impairment Loss of $41.70 million as of 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Notes › Goodwill and Other › Goodwill, Impaired, Accumulated Impairment Loss
us-gaap:GoodwillImpairedAccumulatedImpairmentLoss · last filed 2022-11-09
- 2022-09-30: Goodwill, Impaired, Accumulated Impairment Loss $41.70M.
- 2022-06-30: Goodwill, Impaired, Accumulated Impairment Loss $41.70M.
- 2022-03-31: Goodwill, Impaired, Accumulated Impairment Loss $41.70M.
- 2021-12-31: Goodwill, Impaired, Accumulated Impairment Loss $41.70M.
| Period end | Goodwill, Impaired, Accumulated Impairment Loss |
|---|---|
| 2022-09-30 | $41.70M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $41.70M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $41.70M 10-Q · filed 2022-04-29 |
| 2021-12-31 | $41.70M 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |